Definition
Hemoglobin D (Hb D) is a variant form of the oxygen‑transport protein hemoglobin, resulting from a point mutation in the β‑globin gene (HBB). The most common type, Hb D‑Punjab, involves a substitution of glutamic acid by glutamine at codon 121 (β121 Glu→Gln).
Overview
Hb D is one of several hemoglobinopathies—genetic alterations that affect the structure or synthesis of hemoglobin. It is inherited in an autosomal recessive manner. The variant is especially prevalent in populations from the Punjab region of India and Pakistan, as well as in certain Middle‑Eastern and Mediterranean groups. Heterozygous carriers (Hb D trait) are usually asymptomatic, while homozygous individuals may exhibit mild anemia, microcytosis, or target cells on peripheral blood smear. When co‑inherited with other hemoglobin variants such as sickle‑cell hemoglobin (Hb S) or β‑thalassemia, more severe clinical manifestations can occur.
Etymology/Origin
The designation “Hemoglobin D” follows the convention of assigning alphabetical letters to distinct hemoglobin variants (e.g., Hb S for sickle, Hb C). The “D” label was historically assigned as the fourth new hemoglobin variant described after the initial discoveries of Hb A, Hb S, and Hb C. The suffix “Punjab” is added to specify the most widespread form, reflecting its geographic origin.
Characteristics
| Feature | Details |
|---|---|
| Genetic mutation | HBB: c.364G>A (β121 Glu→Gln). |
| Molecular weight | Comparable to normal hemoglobin A; migration pattern on electrophoresis differs, typically co‑migrating with Hb S on alkaline electrophoresis and with Hb A on acidic electrophoresis. |
| Oxygen affinity | Slightly altered but clinically insignificant; oxygen dissociation curve remains near normal. |
| Prevalence | Estimated carrier frequency up to 1‑2 % in the Punjab region; lower frequencies in other ethnic groups. |
| Clinical significance | • Heterozygotes: Usually asymptomatic. • Homozygotes: Mild hemolytic anemia, microcytosis, possible splenomegaly. • Compound heterozygotes (e.g., Hb D/Hb S): May develop sickle‑cell disease–like symptoms, including vaso‑occlusive crises. |
| Diagnostic methods | Hemoglobin electrophoresis, high‑performance liquid chromatography (HPLC), capillary electrophoresis, and DNA analysis (PCR or sequencing) to confirm the β‑globin mutation. |
| Management | No specific treatment required for carriers or most homozygotes; management focuses on monitoring anemia and, when present, addressing complications of compound hemoglobinopathies. |
Related Topics
- Hemoglobin variants – Other structural hemoglobinopathies such as Hb S (sickle), Hb C, Hb E, and Hb G.
- β‑Globin gene (HBB) – The gene encoding the β‑globin chain of hemoglobin, mutations of which give rise to numerous hemoglobinopathies.
- Thalassemia – Disorders of reduced globin chain synthesis that can coexist with Hb D.
- Sickle‑cell disease – A severe hemoglobinopathy that may be compounded by co‑inheritance of Hb D.
- Hemoglobin electrophoresis – Laboratory technique used to separate and identify hemoglobin variants.
Note: Information presented reflects current scientific consensus as of 2026. Ongoing research may further elucidate the epidemiology and clinical implications of Hemoglobin D.